Warngau, November 28, 2023 AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the expansion of its management team to implement its strategic growth strategy. After taking over the role of Chief Executive Officer (CEO) from Philipp Karbach in June of this year, Sebastian Herzog is strengthening the management team with […]
read moreAMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant.
read moreAMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
read moreAMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor of Drug Delivery at the Faculty of Chemistry and Pharmacy of Ludwig-Maximilians-Universität (LMU) Munich, as a member of its Scientific Advisory Board (SAB). Prof. Merkel is an internationally recognized expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will strengthen AMW’s scientific expertise in sustained-release delivery systems, such as biodegradable implants, and contribute to the company’s strategic development plans. With her appointment, Prof. Merkel succeeds Prof. Dr. Gerhard Winter, who will step down from his position on the Scientific Advisory Board.
read moreAMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.
read moreAMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.
read more